Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 6/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12661153 | 0.95 | HDAC8 (0.36) | GPR119L3MBTL1KDM4ENPC1RAB9A | |
| SCHEMBL933104 | 0.94 | GPR119 (0.36) | DGAT1GPR119L3MBTL1KDM4ENPC1 | |
| SCHEMBL1889126 | 0.93 | CHEK2 (0.35) | DGAT1GPR119L3MBTL1KDM4ENPC1 | |
| SCHEMBL934415 | 0.93 | DGAT1 (0.39) | DGAT1 | |
| SCHEMBL12661185 | 0.91 | HDAC8 (0.35) | DGAT1GPR119L3MBTL1KDM4ENPC1 | |
| SCHEMBL1888626 | 0.91 | DGAT1 (0.37) | DGAT1GPR119L3MBTL1KDM4ENPC1 | |
| SCHEMBL932651 | 0.90 | DGAT1 (0.36) | DGAT1GPR119L3MBTL1KDM4ENPC1 | |
| SCHEMBL1885778 | 0.89 | DGAT1 (0.35) | DGAT1GPR119L3MBTL1KDM4ENPC1 | |
| SCHEMBL1888828 | 0.88 | DGAT1 (0.36) | DGAT1GPR119L3MBTL1KDM4ENPC1 | |
| SCHEMBL932212 | 0.88 | SPHK2 (0.34) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110112100-A1 | Hepatitis C Virus Inhibitors | PFIZER INC. | 2011-05-12 | — | — | US | disclosed |
| US-20110112100-A1 | Hepatitis C Virus Inhibitors | PFIZER INC. | 2011-05-12 | — | — | US | disclosed |
| WO-2011004276-A1 | HEPATITIS C VIRUS INHIBITORS | PFIZER LIMITED (GB) | 2011-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112100-A1 | Hepatitis C Virus Inhibitors | HAVCR2, SLC10A1, HCCS | DGAT1 1994/4885GPR119 2249/4885L3MBTL1 3963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.